Sponsored Research and License Agreements (Details) - USD ($) $ in Millions |
1 Months Ended | 3 Months Ended | |
|---|---|---|---|
Feb. 28, 2017 |
Mar. 31, 2017 |
Sep. 30, 2018 |
|
| Collaborative arrangement | |||
| Collaborations | |||
| Maximum amount of contingent payments receivable | $ 222.9 | ||
| Specified Development Events | Collaborative arrangement | |||
| Collaborations | |||
| Maximum amount of contingent payments receivable | 58.0 | ||
| Specified Regulatory Events | Collaborative arrangement | |||
| Collaborations | |||
| Maximum amount of contingent payments receivable | 123.6 | ||
| Specified Product Launch Events | Collaborative arrangement | |||
| Collaborations | |||
| Maximum amount of contingent payments receivable | $ 41.3 | ||
| BerGenBio | |||
| Collaborations | |||
| Collaborative payment received | $ 3.3 | ||
| Revenue recognized | $ 3.3 |
| X | ||||||||||
- Definition Represents the maximum amount of pre-specified contingent payments receivable under the collaborative and licensing agreement. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of collaboration payment received during the period. No definition available.
|
| X | ||||||||||
- Definition Represents the revenue recognized during the period under the terms of sponsored research and license agreements. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|